Search
Breast Cancer
URCC 19075 **MBMC ONLY** (Temporarily Closed to Enrollment)
Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)
NRG BR007
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
A222004 (JIT – If a possible patient is identified, notify CRA asap as it will take time to open trial through NCORP)
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
URCC-21038
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
S2013: I-CHECKIT
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study
A011801
The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
A191901 **Temporarily Suspended as of 11/16/22** **non-Black women under the age of 50 permanent closure 4/15/22**
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
EA1181 (CompassHER2-pCR) ****The subset of patients with HER2-positive and ER-positive breast cancer with tumors 2.1-3.0 cm and node-negative is CLOSED TO ACCRUAL EFFECTIVE JULY 27, 2022****
Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
URCC 18007
Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue
S1706
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
